

Antidiabetic therapy and diabetic kidney disease

Adjustments of dosages according to eGFR



CKD stage	1–2 eGFR >60 ml/min/1.73 m ²	3a eGFR 45–60 ml/min/1.73 m ²	3b eGFR 30–45 ml/min/1.73 m ²	4 eGFR 15–30 ml/min/1.73 m ²	5 Haemodialysis
Insulins		Decrease dose			
Glinides					
Novonorm® Repaglinide	0.5–12 mg/d				
Starlix® Nateglinide	60–360 mg/d		60 mg/dose		
DPP-IV inhibitors					
Januvia® Sitagliptin	50–100 mg/d	50 mg/d		25 mg/d	
Trajenta® Linagliptin	5 mg/d				
Galvus® Vildagliptin	2 x 50 mg/d	1 x 50 mg/d			
Vipidia® Alogliptin	25 mg/d	12.5 mg/d		6.25 mg/d	
Onglyza® Saxagliptin	5 mg/d		2.5 mg/d		
GLP1R agonists					
Byetta® Exenatide	10 µg 2x/d		5 µg 2x/d		
Bydureon® Exenatide	2 mg/w				
Victoza® Liraglutide	0.6–1.8 mg/d				
Lyxumia® Lixisenatide	10–20 µg/d				
Trulicity® Dulaglutide	0.75–1.5 mg/w				
Rybelsus® Semaglutide	3–14 mg/d				
Ozempic® Semaglutide	0.25–1 mg/w				
Thiazolidinediones					
Actos® Pioglitazone	15–45 mg/d				
Metformin					
Glucophage® Metformin	500–2550 mg/d	500–1500 mg/d	500–1000 mg/d do not initiate		
SGLT2 inhibitors					
Invokana® Canagliflozin	100–300 mg/d	100 mg/d	Initiation only if ACR >30 mg/mmol	OK until dialysis if ACR >30 mg/mmol. Do not initiate	
Jardiance® Empagliflozin	10 mg/d		If symptomatic LV HF	If symptomatic LV HF →20 ml/min/1.73 m ²	
Forxiga® Dapagliflozin	5–10 mg/d		If HFrEF or CKD	If CKD initiation →25 ml/min/1.73 m ² OK until dialysis	
Ertugliflozin® Steglatro	5 mg/d				
Sulfonylureas					
Diamicron® Gliclazide	30–120 mg/d				
Daonil® Glibenclamide	2.5–10 mg/d				
Amaryl® Glimepiride	1–6 mg/d				

** We recommend, evidence high
* We recommend, evidence moderate

Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) (2023)

